Polysaccharides: Candidates of promising vaccine adjuvants
Authors:
- 1 January 2015
- journal article
- review article
- Published by International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA) in Drug Discoveries & Therapeutics
- Vol. 9 (2) , 88-93
Abstract
Aluminium-based adjuvants remain the only adjuvants approved for human use in the USA for over 80 years because of alum's simplicity, tolerability, safety and cost-efficiency. Recent development of vaccines, especially the increasing applications of recombinant subunit and synthetic vaccines, makes aluminium adjuvants cannot stimulate enough immunity to the antigens, since aluminium adjuvants can only induce Th2 type immune responses. So, novel adjuvants are urgent to make up the disadvantages of aluminium adjuvants. However, some major hurdles need to be overcome, not only the scientific knowledge of adjuvants but also unacceptable side-effects and toxicity. A number of carbohydrate-based polysaccharides from plant, bacterial, yeast and synthetic sources can act as pathogen-associated molecular patterns (PAMPs) and recognize pattern recognition receptors (PRRs) on immune cells, followed by triggering innate immunity and regulating adaptive immunity. What is more, polysaccharides are safe and biodegradable without tissue deposits as observed in aluminium adjuvants. Therefore, polysaccharide-based compounds and formulations are potential vaccine adjuvant candidates. Here, we mainly review polysaccharide-based adjuvants investigated in recent years.Keywords
This publication has 47 references indexed in Scilit:
- The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effectVaccine, 2013
- The history of MF59 ® adjuvant: a phoenix that arose from the ashesExpert Review of Vaccines, 2013
- Carbohydrate-based immune adjuvantsExpert Review of Vaccines, 2011
- Delta inulin: a novel, immunologically active, stable packing structure comprising -D-[2 -> 1] poly(fructo-furanosyl) -D-glucose polymersGlycobiology, 2010
- New adjuvants for human vaccinesCurrent Opinion in Immunology, 2010
- The path to a successful vaccine adjuvant – ‘The long and winding road’Drug Discovery Today, 2009
- Carbohydrate moieties as vaccine candidates: Meeting summaryVaccine, 2008
- Inulin‐derived adjuvants efficiently promote both Th1 and Th2 immune responsesImmunology & Cell Biology, 2004
- Vaccine adjuvants: Current state and future trendsImmunology & Cell Biology, 2004
- Towards the rational design of Th1 adjuvantsVaccine, 2001